Anteris Technologies GlobalAVR +1.62%23 Cyclically Adjusted PS Ratio is 111.44 as of Jun. 26, 2026, which is 160% above its 10-year median of 42.86. GuruFocus rates AVR with a GF Score™ of 23/100. The stock has 7 warning signs investors should review. Among 526 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 99.62% on this metric.
The historical rank and industry rank for Anteris Technologies Global's Cyclically Adjusted PS Ratio or its related term are showing as below:
AVR'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 20.58 Med: 42.86 Max: 109.67
Current: 108.57
During the past years, Anteris Technologies Global's highest Cyclically Adjusted PS Ratio was 109.67. The lowest was 20.58. And the median was 42.86.
AVR's Cyclically Adjusted PS Ratio is ranked worse than 99.62% of 526
companies
in the Medical Devices & Instruments industry
Industry Median: 2.22
vs AVR: 108.57
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Anteris Technologies Global's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.006. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.09 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Anteris Technologies Global (NAS:AVR) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Anteris Technologies Global Cyclically Adjusted PS Ratio Related Terms
Anteris Technologies Global Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global Cyclically Adjusted PS Ratio Chart
AVR vs INMD, QDEL, SSII: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Anteris Technologies Global's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's Cyclically Adjusted PS Ratio falls into.
Anteris Technologies Global Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 111.44 mean?
Anteris Technologies Global (AVR) has a Cyclically Adjusted PS Ratio of 111.44 as of Jun. 26, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anteris Technologies Global and its competitors. This is 160% above median its historical median of 42.86. Over the past decade, Anteris Technologies Global's Cyclically Adjusted PS Ratio has ranged from 20.58 to 109.67. According to the industry distribution chart, Anteris Technologies Global ranks #524 out of 526 companies in the Medical Devices & Instruments industry, placing it in the top 99.6%.
Is Anteris Technologies Global's Cyclically Adjusted PS Ratio too high?
Anteris Technologies Global's current Cyclically Adjusted PS Ratio of 111.44 is 160% above median its 10-year median of 42.86. Over the past 10 years, this metric has ranged from a low of 20.58 to a high of 109.67. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.22. Anteris Technologies Global's value of 111.44 is 4919.8% above this industry median. Based on the distribution chart, Anteris Technologies Global ranks #524 out of 526 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Cyclically Adjusted PS Ratio compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #524 out of 526 companies for Cyclically Adjusted PS Ratio. This places Anteris Technologies Global in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.22. Anteris Technologies Global's value of 111.44 is 4919.8% above this benchmark. Historically, Anteris Technologies Global's own Cyclically Adjusted PS Ratio has ranged from 20.58 to 109.67 over the past decade. While the company's 10-year median is 42.86 vs. the industry median of 2.22, Anteris Technologies Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.22, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current Cyclically Adjusted PS Ratio of 111.44 is 4919.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current Cyclically Adjusted PS Ratio is 111.44, which is 160% above median its own 10-year median of 42.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (AVR) has a current Cyclically Adjusted PS Ratio of 111.44. The current Cyclically Adjusted PS Ratio is 111.44, which is 160% above median its 10-year median of 42.86 and 4919.8% above the Medical Devices & Instruments industry median of 2.22. Anteris Technologies Global's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Anteris Technologies Global (AVR), the current Cyclically Adjusted PS Ratio is 111.44 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
23GF Score
Get the complete analysis for AVR
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVR has been successfully added to your 
